Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.

ABSTRACT: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. In this study, we compared immune responses to the BNT162b2 mRNA Coronavirus Disease 2019 vaccine in patients with solid tumors (n = 53) who were on active cytotoxic anti-cancer therapy to a control cohort of participants without cancer (n = 50). Neutralizing antibodies were detected in 67% of patients with cancer after the first immunization, followed by a threefold increase in median titers after the second dose. Similar patterns were observed for spike protein-specific serum antibodies and T cells, but the magnitude of each of these responses was diminished relative to the control cohort. In most patient

SUBMITTER: Shroff RT 

PROVIDER: S-EPMC9004706 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature